Liquid Biotech USA, Inc. is pleased to announce being selected as a Finalist in the 2016 Enterprise Awards Life Sciences Startup Category

PHILADELPHIA, Feb. 16, 2016 /PRNewswire/ -- The Company is honored to announce that it has been selected as a finalist for the 2016 Enterprise Awards for Life Sciences Startup.  The Enterprise Awards, presented by PACT and in partnership with KPMG, recognizes and honors leadership and outstanding achievement in the technology, healthcare and life sciences industries throughout the Philadelphia area.  The criteria for the award for a Life Sciences Startup Company includes being in operation for three years or less, a product or innovative technology with high potential for rapid market growth, as well as a management team with a proven record of accomplishment.

"We are delighted to have been selected as a finalist in this year's Enterprise Awards for Life Sciences Startup," said Dr. Philip M. Sass, Chairman, President, and CEO of Liquid Biotech USA, Inc. "It is exciting for us to be recognized for this prestigious award. Considering how young our organization is, we are thrilled to have been recognized so early in the development of our technology, which is to develop a highly sensitive and non-invasive cancer diagnostic to support physicians' efforts to treat metastatic cancer."

"Being selected as a finalist for such a prestigious award in the Life Sciences Startup Category, is both an honor and a testament to our innovative technology," stated Jeffrey M. Janco, Executive Vice President, Chief Operating Officer and member of the Board of Liquid Biotech USA, Inc.

About Liquid Biotech USA:

Liquid Biotech USA, Inc.'s mission is to employ our novel, proprietary technology to isolate, enumerate and genetically analyze circulating tumor cells (CTCs) in cancer patients in order to develop sensitive, non-invasive diagnostic testing to enable physicians to better manage their patients' cancer.  In addition, we support internal, corporate, and academic research by isolating and analyzing individual CTCs, employing next generation DNA sequencing technology to discover novel cancer driver genes to support drug development efforts of our partners, develop next generation stage specific cancer biomarkers, and support companion diagnostics.

Company Contact:

Dr. Philip M. Sass
Chairman, President and CEO
Liquid Biotech USA, Inc.
[email protected]

SOURCE Liquid Biotech USA, Inc.